Compounds > quinazolines
Page last updated: 2024-08-21

quinazolines and aee 788

quinazolines has been researched along with aee 788 in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (35.71)29.6817
2010's9 (64.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blüthner, T; Caca, K; Feisthammel, J; Kamenz, T; Kluge, A; Mössner, J; Tannapfel, A; Wiedmann, M1
Marais, R; Niculescu-Duvaz, D; Springer, C; Whittaker, S1
Boggon, TJ; Eck, MJ; Greulich, H; Li, Y; Meyerson, M; Woo, MS; Yun, CH1
Baker, CH; Bekele, N; Fidler, IJ; Herbst, RS; Langley, RR; O'Reilly, MS; Onn, A; Tang, XM; Tsan, RZ; Wu, W1
Finn, RS; Zhu, AX1
Ikemura, S; Ishizaka, A; Kawada, I; Nakachi, I; Nakayama, S; Naoki, K; Sato, T; Satomi, R; Soejima, K; Terai, H; Watanabe, H; Yasuda, H; Yoda, S1
Berezowska, S; Brockhoff, G; Busch, R; Diermeier-Daucher, S; Duyster, J; Grosu, AL; Schlegel, J1
Coveney, PV; Wan, S1
Lamorte, G; Meco, D; Pallini, R; Patriarca, V; Riccardi, R; Servidei, T; Trivieri, N; Vellone, VG; Zannoni, GF1
Abagyan, R; Behera, R; Katiyar, S; Kufareva, I; Mensa-Wilmot, K; Ogata, Y; Pollastri, M; Thomas, SM1
Bollu, LR; Gao, G; Huang, WC; Hung, MC; Ren, J; Su, F; Weihua, Z; Xu, L1
Behera, R; Mensa-Wilmot, K; Thomas, SM1
Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H1
Birkeland, AC; Bradford, CR; Brenner, JC; Carey, TE; Foltin, SK; Komarck, CM; Ludwig, ML; Mann, JE; McHugh, JB; Michmerhuizen, NL; Prince, ME; Sandelski, MM; Scott, MV; Spector, ME; Tillman, BN; Yanik, M1

Reviews

1 review(s) available for quinazolines and aee 788

ArticleYear
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
    Expert review of anticancer therapy, 2009, Volume: 9, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Purines; Quinazolines; RNA, Small Interfering; Treatment Outcome; Vascular Endothelial Growth Factor A

2009

Other Studies

13 other study(ies) available for quinazolines and aee 788

ArticleYear
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Anti-cancer drugs, 2006, Volume: 17, Issue:7

    Topics: Animals; Antineoplastic Agents; Biliary Tract Neoplasms; Cell Division; Cell Line, Tumor; Cholangiocarcinoma; DNA, Complementary; DNA, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Purines; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2

2006
The EGF receptor Hokey-Cokey.
    Cancer cell, 2007, Volume: 11, Issue:3

    Topics: Antineoplastic Agents; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lapatinib; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Purines; Quinazolines; Staurosporine

2007
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
    Cancer cell, 2007, Volume: 11, Issue:3

    Topics: Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Crystallography, X-Ray; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Purines; Quinazolines; Staurosporine

2007
Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:10

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Phosphorylation; Purines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor alpha; Xenograft Model Antitumor Assays

2007
The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Molecular cancer research : MCR, 2010, Volume: 8, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Humans; Immunosuppressive Agents; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Purines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; Tumor Cells, Cultured

2010
Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    International journal of molecular medicine, 2010, Volume: 26, Issue:5

    Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Glioblastoma; Humans; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Tyrphostins

2010
Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs.
    Journal of the Royal Society, Interface, 2011, Aug-07, Volume: 8, Issue:61

    Topics: Computer Simulation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Structure, Tertiary; Purines; Quinazolines

2011
Effects of epidermal growth factor receptor blockade on ependymoma stem cells in vitro and in orthotopic mouse models.
    International journal of cancer, 2012, Sep-01, Volume: 131, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cell Proliferation; Child; Ependymoma; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Humans; Immunoenzyme Techniques; In Vitro Techniques; Mice; Neoplastic Stem Cells; Purines; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2012
Lapatinib-binding protein kinases in the African trypanosome: identification of cellular targets for kinase-directed chemical scaffolds.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Adenosine Triphosphate; Amino Acid Sequence; Chromatography, Affinity; ErbB Receptors; HeLa Cells; Humans; Lapatinib; Ligands; Models, Molecular; Molecular Sequence Data; Molecular Targeted Therapy; Morpholines; NAD; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Purines; Quinazolines; Structural Homology, Protein; Trypanosoma brucei brucei

2013
EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.
    The Prostate, 2013, Volume: 73, Issue:13

    Topics: Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Male; Phosphorylation; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Sodium-Glucose Transporter 1

2013
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:4

    Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African

2014
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
    Amino acids, 2016, Volume: 48, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine

2016
Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.
    JAMA otolaryngology-- head & neck surgery, 2016, 06-01, Volume: 142, Issue:6

    Topics: Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Carbamates; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; ErbB Receptors; Gene Expression Profiling; Humans; Hydroxybutyrates; Immunohistochemistry; Laryngeal Neoplasms; Mouth Neoplasms; Mutation; Purines; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Triazines

2016